Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
Despite the company’s recent market outperformance, coverage remains broadly constructive, with analysts continuing to project meaningful gains for Eli Lilly’s stock.
THE APEX TIMES
THE APEX TIMES
Lilly (LLY) moved higher after reports of a new direct-to-consumer partnership with CVS Health tied to its weight-loss medicines, in a market reaction that also referenced a strong Q2 update and optimistic forward guidance.
THE APEX TIMES
Market chatter around continued strength in GLP-1 demand helped lift Eli Lilly stock on Aug. 5, according to financial media coverage.
THE APEX TIMES
Eli Lilly and Co. reported a sharp second-quarter revenue increase tied to its incretin-based obesity treatment Zepbound and said it is raising its full-year 2026 guidance, pointing to continued strength in blockbuster sales and expanding international presence.
THE APEX TIMES
The drugmaker said revenue expectations moved higher as its weight-loss and diabetes franchises, anchored by Mounjaro and Zepbound, accounted for nearly two-thirds of a recent quarter’s sales, according to a report.
THE APEX TIMES
Eli Lilly reported a sharp rebound in sales for the quarter, sending its stock higher, as momentum in GLP-1 medicines appeared to widen its competitive gap with Novo Nordisk.
THE APEX TIMES
A new market note argues the healthcare sector has been overlooked this year and flags a basket of stocks, including Eli Lilly (LLY) and McKesson, as potential beneficiaries if investors broaden beyond the year’s biggest winners.
THE APEX TIMES
Eli Lilly opened Wednesday’s session on a sharply higher note after reporting a blowout quarter, reinforcing investor focus on the durability of demand for its weight-loss pipeline and manufacturing ramp.
THE APEX TIMES
A new collaboration between CVS Health and Eli Lilly is aimed at improving patient access to GLP-1 medicines, according to a report cited by Yahoo Finance, in a week when investors also scanned major healthcare names for second-quarter outlines.
